Cargando…

Cardiac symptom burden and arrhythmia recurrence drives digital health use: results from the iHEART randomized controlled trial

AIMS: Digital health can transform the management of atrial fibrillation (AF) and enable patients to take a central role in detecting symptoms and self-managing AF. There is a gap in understanding factors that support sustained use of digital health tools for patients with AF. This study identified...

Descripción completa

Detalles Bibliográficos
Autores principales: Masterson Creber, Ruth M, Reading Turchioe, Meghan, Biviano, Angelo, Caceres, Billy, Garan, Hasan, Goldenthal, Isaac, Koleck, Theresa, Mitha, Shazia, Hickey, Kathleen, Bakken, Suzanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560656/
https://www.ncbi.nlm.nih.gov/pubmed/34009326
http://dx.doi.org/10.1093/eurjcn/zvab009
_version_ 1784592962782494720
author Masterson Creber, Ruth M
Reading Turchioe, Meghan
Biviano, Angelo
Caceres, Billy
Garan, Hasan
Goldenthal, Isaac
Koleck, Theresa
Mitha, Shazia
Hickey, Kathleen
Bakken, Suzanne
author_facet Masterson Creber, Ruth M
Reading Turchioe, Meghan
Biviano, Angelo
Caceres, Billy
Garan, Hasan
Goldenthal, Isaac
Koleck, Theresa
Mitha, Shazia
Hickey, Kathleen
Bakken, Suzanne
author_sort Masterson Creber, Ruth M
collection PubMed
description AIMS: Digital health can transform the management of atrial fibrillation (AF) and enable patients to take a central role in detecting symptoms and self-managing AF. There is a gap in understanding factors that support sustained use of digital health tools for patients with AF. This study identified predictors of Alivecor(®) KardiaMobile ECG monitor usage among patients with AF enrolled in the iPhone(®)Helping Evaluate Atrial fibrillation Rhythm through Technology (iHEART) randomized controlled trial. METHODS AND RESULTS: We analysed data from 105 English and Spanish-speaking adults with AF enrolled in the intervention arm of the iHEART trial. The iHEART intervention included smartphone-based electrocardiogram self-monitoring with Alivecor(®) KardiaMobile and triweekly text messages for 6 months. The primary outcome was use of Alivecor(®) categorized as: infrequent (≤5 times/week), moderate (>5 times and ≤11 times/week), and frequent (>11 times/week). We applied multinomial logistic regression modelling to characterize frequency and predictors of use. Of the 105 participants, 25% were female, 75% were White, and 45% were ≥65 years of age. Premature atrial contractions (PACs) [adjusted odds ratio (OR): 1.23, 1.08–1.40, P = 0.002] predicted frequent as compared to infrequent use. PACs (adjusted OR: 1.17, 95% confidence interval 1.06–1.30, P = 0.003), lower symptom burden (adjusted OR: 1.06, 1.01–1.11, P = 0.02), and less treatment concern (adjusted OR: 0.96, 0.93–0.99, P = 0.02) predicted moderate as compared to infrequent use. CONCLUSIONS: Frequent use of AliveCor(®) is associated with AF symptoms and potentially symptomatic cardiac events. Symptom burden and frequency should be measured and incorporated into analyses of future digital health trials for AF management.
format Online
Article
Text
id pubmed-8560656
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-85606562022-03-04 Cardiac symptom burden and arrhythmia recurrence drives digital health use: results from the iHEART randomized controlled trial Masterson Creber, Ruth M Reading Turchioe, Meghan Biviano, Angelo Caceres, Billy Garan, Hasan Goldenthal, Isaac Koleck, Theresa Mitha, Shazia Hickey, Kathleen Bakken, Suzanne Eur J Cardiovasc Nurs Original Articles AIMS: Digital health can transform the management of atrial fibrillation (AF) and enable patients to take a central role in detecting symptoms and self-managing AF. There is a gap in understanding factors that support sustained use of digital health tools for patients with AF. This study identified predictors of Alivecor(®) KardiaMobile ECG monitor usage among patients with AF enrolled in the iPhone(®)Helping Evaluate Atrial fibrillation Rhythm through Technology (iHEART) randomized controlled trial. METHODS AND RESULTS: We analysed data from 105 English and Spanish-speaking adults with AF enrolled in the intervention arm of the iHEART trial. The iHEART intervention included smartphone-based electrocardiogram self-monitoring with Alivecor(®) KardiaMobile and triweekly text messages for 6 months. The primary outcome was use of Alivecor(®) categorized as: infrequent (≤5 times/week), moderate (>5 times and ≤11 times/week), and frequent (>11 times/week). We applied multinomial logistic regression modelling to characterize frequency and predictors of use. Of the 105 participants, 25% were female, 75% were White, and 45% were ≥65 years of age. Premature atrial contractions (PACs) [adjusted odds ratio (OR): 1.23, 1.08–1.40, P = 0.002] predicted frequent as compared to infrequent use. PACs (adjusted OR: 1.17, 95% confidence interval 1.06–1.30, P = 0.003), lower symptom burden (adjusted OR: 1.06, 1.01–1.11, P = 0.02), and less treatment concern (adjusted OR: 0.96, 0.93–0.99, P = 0.02) predicted moderate as compared to infrequent use. CONCLUSIONS: Frequent use of AliveCor(®) is associated with AF symptoms and potentially symptomatic cardiac events. Symptom burden and frequency should be measured and incorporated into analyses of future digital health trials for AF management. Oxford University Press 2021-05-02 /pmc/articles/PMC8560656/ /pubmed/34009326 http://dx.doi.org/10.1093/eurjcn/zvab009 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Articles
Masterson Creber, Ruth M
Reading Turchioe, Meghan
Biviano, Angelo
Caceres, Billy
Garan, Hasan
Goldenthal, Isaac
Koleck, Theresa
Mitha, Shazia
Hickey, Kathleen
Bakken, Suzanne
Cardiac symptom burden and arrhythmia recurrence drives digital health use: results from the iHEART randomized controlled trial
title Cardiac symptom burden and arrhythmia recurrence drives digital health use: results from the iHEART randomized controlled trial
title_full Cardiac symptom burden and arrhythmia recurrence drives digital health use: results from the iHEART randomized controlled trial
title_fullStr Cardiac symptom burden and arrhythmia recurrence drives digital health use: results from the iHEART randomized controlled trial
title_full_unstemmed Cardiac symptom burden and arrhythmia recurrence drives digital health use: results from the iHEART randomized controlled trial
title_short Cardiac symptom burden and arrhythmia recurrence drives digital health use: results from the iHEART randomized controlled trial
title_sort cardiac symptom burden and arrhythmia recurrence drives digital health use: results from the iheart randomized controlled trial
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560656/
https://www.ncbi.nlm.nih.gov/pubmed/34009326
http://dx.doi.org/10.1093/eurjcn/zvab009
work_keys_str_mv AT mastersoncreberruthm cardiacsymptomburdenandarrhythmiarecurrencedrivesdigitalhealthuseresultsfromtheiheartrandomizedcontrolledtrial
AT readingturchioemeghan cardiacsymptomburdenandarrhythmiarecurrencedrivesdigitalhealthuseresultsfromtheiheartrandomizedcontrolledtrial
AT bivianoangelo cardiacsymptomburdenandarrhythmiarecurrencedrivesdigitalhealthuseresultsfromtheiheartrandomizedcontrolledtrial
AT caceresbilly cardiacsymptomburdenandarrhythmiarecurrencedrivesdigitalhealthuseresultsfromtheiheartrandomizedcontrolledtrial
AT garanhasan cardiacsymptomburdenandarrhythmiarecurrencedrivesdigitalhealthuseresultsfromtheiheartrandomizedcontrolledtrial
AT goldenthalisaac cardiacsymptomburdenandarrhythmiarecurrencedrivesdigitalhealthuseresultsfromtheiheartrandomizedcontrolledtrial
AT kolecktheresa cardiacsymptomburdenandarrhythmiarecurrencedrivesdigitalhealthuseresultsfromtheiheartrandomizedcontrolledtrial
AT mithashazia cardiacsymptomburdenandarrhythmiarecurrencedrivesdigitalhealthuseresultsfromtheiheartrandomizedcontrolledtrial
AT hickeykathleen cardiacsymptomburdenandarrhythmiarecurrencedrivesdigitalhealthuseresultsfromtheiheartrandomizedcontrolledtrial
AT bakkensuzanne cardiacsymptomburdenandarrhythmiarecurrencedrivesdigitalhealthuseresultsfromtheiheartrandomizedcontrolledtrial